国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2014年
8期
702-706
,共5页
陈成%陈永忠%邹襄谷%林秀明%陈慧
陳成%陳永忠%鄒襄穀%林秀明%陳慧
진성%진영충%추양곡%림수명%진혜
丹参多酚酸盐%心力衰竭%去甲肾上腺素%血管紧张素-Ⅱ%肿瘤坏死因子-α
丹參多酚痠鹽%心力衰竭%去甲腎上腺素%血管緊張素-Ⅱ%腫瘤壞死因子-α
단삼다분산염%심력쇠갈%거갑신상선소%혈관긴장소-Ⅱ%종류배사인자-α
Salvianolate%Heart failure%NE%Ang-Ⅱ%TNF-α
目的：探讨丹参多酚酸盐对心衰模型大鼠去甲肾上腺素（noradrenaline，NE）、血管紧张素-Ⅱ（angiotension-Ⅱ，Ang-Ⅱ）、肿瘤坏死因子-α（tumor necrosis factor-a，TNF-a）的影响。方法60只雄性SD大鼠采用随机数字表法分为6组各10只，即正常对照组、模型组、卡托普利组、丹参多酚酸盐低剂量、丹参多酚酸盐高剂量组、卡托普利联合丹参高剂量组。除正常对照组，其余5组大鼠腹腔注射阿霉素制造心衰模型。造模的同时，各组开始相关干预。8周后，检测各组大鼠的左室收缩压（left ventricular systolic pressure，LVSP）、左室舒张末压（left ventricular end-diastolic pressure，LVDP）、左室内压最大上升速度（＋dp/dtmax）、左室内压最大下降速度（-dp/dtmax），血清NE、Ang-Ⅱ、TNF-α水平。Western-blot方法检测心肌Ang-Ⅱ、TNF-α的表达。结果与模型组LVSP、LVDP、＋dp/dtmax、-dp/dtmax [分别为（90.77±14.75）mmHg、（22.52±2.58）mmHg、（3290.16±109.61）mmHg/s、（3114.07±112.39）mmHg/s]比较，丹参多酚酸盐高剂量组[分别为（114.10±13.71）mmHg、（19.97±1.14）mmHg、（3504.97±163.94）mmHg/s、（3303.02±121.98）mmHg/s]，卡托普利组[分别为（119.77±15.70）mmHg、（18.88±2.43）mmHg、（3562.78±148.16）mmHg/s、（3372.93±156.13）mmHg/s]，卡托普利联合丹参高剂量组[分别为（141.18±15.42）mmHg、（15.58±1.46）mmHg、（3766.56±159.93）mmHg/s、（3566.70±154.57）mmHg/s]差异均有统计学意义（P＜0.05或0.01），且卡托普利联合丹参高剂量组与卡托普利组比较，差异有统计学意义（P＜0.05）。与模型组血清NE、Ang-Ⅱ、TNF-α水平[（85.06±9.07）ng/ml、（180.11±25.45）pg/ml、（205.80±15.73）pg/ml]比较，丹参多酚酸盐高剂量组[（75.33±8.60）ng/ml、（149.21±25.39）pg/ml、（188.84±13.79）pg/ml]、卡托普利组[（71.49±6.21）ng/ml、（139.15±24.83）pg/ml、（183.73±10.99）pg/ml]、卡托普利联合丹参高剂量组[（60.02±7.38）ng/ml、（110.68±28.63）pg/ml、（165.93±16.22）pg/ml]均有不同程度降低，差异均有统计学意义（P＜0.05或0.01），且卡托普利联合丹参高剂量组低于卡托普利组（P＜0.05）。与模型组心肌 Ang-Ⅱ、TNF-α[（1.043±0.044）、（1.167±0.048）]表达比较，丹参多酚酸盐高剂量组[（0.981±0.024）、（1.069±0.055）]、卡托普利组[（0.954±0.031）、（1.046±0.053）]、卡托普利联合丹参高剂量组[（0.886±0.044）、（0.955±0.038）]均降低（P＜0.05或＜0.01），且卡托普利联合丹参高剂量组低于卡托普利组（P＜0.05）。结论丹参多酚酸盐可降低心衰大鼠血清NE、Ang-Ⅱ、TNF-α水平，减少心肌Ang-Ⅱ、TNF-α表达。
目的：探討丹參多酚痠鹽對心衰模型大鼠去甲腎上腺素（noradrenaline，NE）、血管緊張素-Ⅱ（angiotension-Ⅱ，Ang-Ⅱ）、腫瘤壞死因子-α（tumor necrosis factor-a，TNF-a）的影響。方法60隻雄性SD大鼠採用隨機數字錶法分為6組各10隻，即正常對照組、模型組、卡託普利組、丹參多酚痠鹽低劑量、丹參多酚痠鹽高劑量組、卡託普利聯閤丹參高劑量組。除正常對照組，其餘5組大鼠腹腔註射阿黴素製造心衰模型。造模的同時，各組開始相關榦預。8週後，檢測各組大鼠的左室收縮壓（left ventricular systolic pressure，LVSP）、左室舒張末壓（left ventricular end-diastolic pressure，LVDP）、左室內壓最大上升速度（＋dp/dtmax）、左室內壓最大下降速度（-dp/dtmax），血清NE、Ang-Ⅱ、TNF-α水平。Western-blot方法檢測心肌Ang-Ⅱ、TNF-α的錶達。結果與模型組LVSP、LVDP、＋dp/dtmax、-dp/dtmax [分彆為（90.77±14.75）mmHg、（22.52±2.58）mmHg、（3290.16±109.61）mmHg/s、（3114.07±112.39）mmHg/s]比較，丹參多酚痠鹽高劑量組[分彆為（114.10±13.71）mmHg、（19.97±1.14）mmHg、（3504.97±163.94）mmHg/s、（3303.02±121.98）mmHg/s]，卡託普利組[分彆為（119.77±15.70）mmHg、（18.88±2.43）mmHg、（3562.78±148.16）mmHg/s、（3372.93±156.13）mmHg/s]，卡託普利聯閤丹參高劑量組[分彆為（141.18±15.42）mmHg、（15.58±1.46）mmHg、（3766.56±159.93）mmHg/s、（3566.70±154.57）mmHg/s]差異均有統計學意義（P＜0.05或0.01），且卡託普利聯閤丹參高劑量組與卡託普利組比較，差異有統計學意義（P＜0.05）。與模型組血清NE、Ang-Ⅱ、TNF-α水平[（85.06±9.07）ng/ml、（180.11±25.45）pg/ml、（205.80±15.73）pg/ml]比較，丹參多酚痠鹽高劑量組[（75.33±8.60）ng/ml、（149.21±25.39）pg/ml、（188.84±13.79）pg/ml]、卡託普利組[（71.49±6.21）ng/ml、（139.15±24.83）pg/ml、（183.73±10.99）pg/ml]、卡託普利聯閤丹參高劑量組[（60.02±7.38）ng/ml、（110.68±28.63）pg/ml、（165.93±16.22）pg/ml]均有不同程度降低，差異均有統計學意義（P＜0.05或0.01），且卡託普利聯閤丹參高劑量組低于卡託普利組（P＜0.05）。與模型組心肌 Ang-Ⅱ、TNF-α[（1.043±0.044）、（1.167±0.048）]錶達比較，丹參多酚痠鹽高劑量組[（0.981±0.024）、（1.069±0.055）]、卡託普利組[（0.954±0.031）、（1.046±0.053）]、卡託普利聯閤丹參高劑量組[（0.886±0.044）、（0.955±0.038）]均降低（P＜0.05或＜0.01），且卡託普利聯閤丹參高劑量組低于卡託普利組（P＜0.05）。結論丹參多酚痠鹽可降低心衰大鼠血清NE、Ang-Ⅱ、TNF-α水平，減少心肌Ang-Ⅱ、TNF-α錶達。
목적：탐토단삼다분산염대심쇠모형대서거갑신상선소（noradrenaline，NE）、혈관긴장소-Ⅱ（angiotension-Ⅱ，Ang-Ⅱ）、종류배사인자-α（tumor necrosis factor-a，TNF-a）적영향。방법60지웅성SD대서채용수궤수자표법분위6조각10지，즉정상대조조、모형조、잡탁보리조、단삼다분산염저제량、단삼다분산염고제량조、잡탁보리연합단삼고제량조。제정상대조조，기여5조대서복강주사아매소제조심쇠모형。조모적동시，각조개시상관간예。8주후，검측각조대서적좌실수축압（left ventricular systolic pressure，LVSP）、좌실서장말압（left ventricular end-diastolic pressure，LVDP）、좌실내압최대상승속도（＋dp/dtmax）、좌실내압최대하강속도（-dp/dtmax），혈청NE、Ang-Ⅱ、TNF-α수평。Western-blot방법검측심기Ang-Ⅱ、TNF-α적표체。결과여모형조LVSP、LVDP、＋dp/dtmax、-dp/dtmax [분별위（90.77±14.75）mmHg、（22.52±2.58）mmHg、（3290.16±109.61）mmHg/s、（3114.07±112.39）mmHg/s]비교，단삼다분산염고제량조[분별위（114.10±13.71）mmHg、（19.97±1.14）mmHg、（3504.97±163.94）mmHg/s、（3303.02±121.98）mmHg/s]，잡탁보리조[분별위（119.77±15.70）mmHg、（18.88±2.43）mmHg、（3562.78±148.16）mmHg/s、（3372.93±156.13）mmHg/s]，잡탁보리연합단삼고제량조[분별위（141.18±15.42）mmHg、（15.58±1.46）mmHg、（3766.56±159.93）mmHg/s、（3566.70±154.57）mmHg/s]차이균유통계학의의（P＜0.05혹0.01），차잡탁보리연합단삼고제량조여잡탁보리조비교，차이유통계학의의（P＜0.05）。여모형조혈청NE、Ang-Ⅱ、TNF-α수평[（85.06±9.07）ng/ml、（180.11±25.45）pg/ml、（205.80±15.73）pg/ml]비교，단삼다분산염고제량조[（75.33±8.60）ng/ml、（149.21±25.39）pg/ml、（188.84±13.79）pg/ml]、잡탁보리조[（71.49±6.21）ng/ml、（139.15±24.83）pg/ml、（183.73±10.99）pg/ml]、잡탁보리연합단삼고제량조[（60.02±7.38）ng/ml、（110.68±28.63）pg/ml、（165.93±16.22）pg/ml]균유불동정도강저，차이균유통계학의의（P＜0.05혹0.01），차잡탁보리연합단삼고제량조저우잡탁보리조（P＜0.05）。여모형조심기 Ang-Ⅱ、TNF-α[（1.043±0.044）、（1.167±0.048）]표체비교，단삼다분산염고제량조[（0.981±0.024）、（1.069±0.055）]、잡탁보리조[（0.954±0.031）、（1.046±0.053）]、잡탁보리연합단삼고제량조[（0.886±0.044）、（0.955±0.038）]균강저（P＜0.05혹＜0.01），차잡탁보리연합단삼고제량조저우잡탁보리조（P＜0.05）。결론단삼다분산염가강저심쇠대서혈청NE、Ang-Ⅱ、TNF-α수평，감소심기Ang-Ⅱ、TNF-α표체。
Objective To investigate the effects of salvianolate on noradrenaline(NE), angiotension-Ⅱ(Ang-Ⅱ)and tumor necrosis factor-α(TNF-α)in rats with congestive heart failure. Methods Sixty male SD rats were randomly divided into 6 groups, the normal control group(NCG), the model group, the captopril group(CAG), the low dosage of salvianolate group(LSG), the high dosage of salvianolate group(HSG), the captopril and high doseage of salvianolate group(CSG). The rats of Congestive Heart Failure were established with peritoneal injection of adriamycin except the rats in normal control group. The rats in normal control group were injected with the equal volume of normal saline once per week for 6 weeks. The medication was started in every group at the same time. Eight weeks later, the Left Ventricular Systolic Pressure(LVSP), Left Ventricular End-diastolic Pressure(LVDP), +dp/dtmax, -dp/dtmax were measured. The serum levels of NE, Ang-Ⅱ and TNF-αwere measured. Protein expressions of Ang-Ⅱ and TNF-αin cardiac muscle were detected by Western blot. Results Compared with the model group[(90.77±14.75)mmHg, (22.52±2.58)mmHg, (3 290.16± 109.61)mmHg/s, (3 114.07±112.39)mmHg/s], HSG[(114.10±13.71)mmHg, (19.97±1.14)mmHg, (3 504.97 ± 163.94)mmHg/s, (3 303.02 ± 121.98)mmHg/s ] and CSG [ (141.18 ± 15.42)mmHg, (15.58 ± 1.46)mmHg, (3 766.56±159.93)mmHg/s, (3 566.70±154.57)mmHg/s]had significant difference in LVSP, LVDP, +dp/dtmax, -dp/dtmax(P<0.05 or 0.01). Compared with the model group[(85.06±9.07)ng/ml, (180.11±25.45)pg/ml, (205.80±15.73)pg/ml], the serum levels of NE, Ang-Ⅱand TNF-αwere decreased in groups of HSG[(75.33±8.60)ng/ml, (149.21±25.39)pg/ml, (188.84±13.79)pg/ml], CAG[(71.49± 6.21)ng/ml, (139.15 ± 24.83)pg/ml, (183.73 ± 10.99)pg/ml ] and CSG [ (60.02 ± 7.38)ng/m, (110.68 ± 28.63)pg/ml, (165.93±16.22)pg/ml]in different degree(P<0.05 or 0.01), those of CSG were significantly lower than CAG(P<0.05). Compared with the model group[(1.043±0.044), (1.167±0.048)], the expression of protein in Ang-Ⅱand TNF-α were decreased in groups of HSG[(0.981±0.024), (1.069±0.055)]CAG [(0.954±0.031), (1.046±0.053)]and CSG[(0.886±0.044), (0.955±0.038)]in different degree(P<0.05 or 0.01), those of CSG were significantly lower than CAG(P<0.05). Conclusion Salvianolate can reduce the serum levels of NE, Ang-Ⅱand TNF-αin rats with congestive heart failure, decrease the expression of Ang-Ⅱand TNF-αin its cardiac muscle, improve the cardiac function.
